Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
110
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis 

Yan Huang1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Juan Hu1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Ting Lu1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Yi Luo1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Jimin Shi1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Wenjun Wu1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Xiaoyan Han1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Weiyan Zheng1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Jingsong He1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Zhen Cai1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
Guoqing Wei1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
,
He Huang1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China
&
Jie Sun1 Bone Marrow Transplantation Center,the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;2 Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;3 Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of China;4 Stem Cell Institute, Zhejiang University, Hangzhou, Zhejiang 310058, People’s Republic of ChinaCorrespondence[email protected] [email protected]
 show all
Pages 4129-4142 | Published online: 08 May 2019

References

  • El Fakih R, Rasheed W, Hawsawi Y, Alsermani M, Hassanein M. Targeting FLT3 mutations in acute myeloid leukemia. Cells. 2018;7(1). doi:10.3390/cells7010004
  • Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089–5102. doi:10.1182/blood-2010-04-26186720705759
  • Bullinger L, Valk PJ. Gene expression profiling in acute myeloid leukemia. J Clin Oncol. 2005;23(26):6296–6305. doi:10.1200/JCO.2005.05.02016155012
  • Frohling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12(6):501–513. doi:10.1016/j.ccr.2007.11.00518068628
  • Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335. 12036858
  • Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–2439. 11290608
  • Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654–3661. doi:10.1182/blood-2006-03-00923316912228
  • Govedarovic N, Marjanovic G. Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia. J BUON. 2011;16(1):108–111. 21674859
  • Canaani J, Labopin M, Huang XJ, et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93(6):736–744. doi:10.1002/ajh.2508229498106
  • Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD. Biological and clinical consequences of NPM1 mutations in AML. Leukemia. 2017;31(4):798–807. doi:10.1038/leu.2017.3028111462
  • Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10):4011–4020. doi:10.1182/blood-2005-08-316716455956
  • Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733–3739. doi:10.1182/blood-2005-06-224816076867
  • Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res. 2006;66(6):3310–3316. doi:10.1158/0008-5472.CAN-05-431616540685
  • Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005;106(10):3618–3620. doi:10.1182/blood-2005-05-217416046528
  • Doehner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-73319627895058
  • Boddu PC, Kadia TM, Garcia-Manero G, et al. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer. 2018;125:1091–1100. 30521114
  • Harada Y, Nagata Y, Kihara R, et al. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res. 2018;66:20–27. doi:10.1016/j.leukres.2018.01.00829360622
  • Versluis J, In ‘T Hout FE, Devillier R, et al. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia. 2017;31(1):26–33. doi:10.1038/leu.2016.18327416910
  • Liu SB, Qiu QC, Bao XB, et al. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Cancer Sci. 2018;109(12):3981–3992. doi:10.1111/cas.1383530320942
  • Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2(20):2744–2754. doi:10.1182/bloodadvances.201802030530341082
  • Oran B, Cortes J, Beitinjaneh A, et al. Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. Biol Blood Marrow Transplant. 2016;22(7):1218–1226. doi:10.1016/j.bbmt.2016.03.02727058617
  • Yuan XQ, Peng L, Zeng WJ, Jiang BY, Li GC, Chen XP. DNMT3A R882 mutations predict a poor prognosis in AML: a meta-analysis from 4474 patients. Medicine. 2016;95(18):e3519. doi:10.1097/MD.000000000000486427149454
  • Patel SS, Kuo FC, Gibson CJ, et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018;131(25):2816–2825. doi:10.1182/blood-2018-01-82846729724895
  • Magina KN, Pregartner G, Zebisch A, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130(7):946–948. doi:10.1182/blood-2017-04-77772228679736
  • Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246–3252. doi:10.1182/blood-2014-10-55150725778528
  • Canaani J, Labopin M, Socie G, et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT. Am J Hematol. 2017;92(7):653–659. doi:10.1002/ajh.2473728370339
  • Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–4336. doi:10.1182/blood-2002-03-077212393746
  • Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997;98(2):433–436. 9266944
  • Dixit A, Chatterjee T, Mishra P, et al. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clin Appl Thromb Hemost. 2007;13(3):292–298. doi:10.1177/107602960730243517636191
  • Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18. doi:10.3109/1042819000905353410975379
  • Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. Leukocytoreduction for acute leukemia. Ther Apher. 2002;6(1):15–23. 11886572
  • Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. doi:10.1056/NEJMoa130168923634996
  • Loghavi S, Zuo Z, Ravandi F, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014;7:74. doi:10.1186/s13045-014-0074-425281355
  • Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742–750. doi:10.1200/JCO.2011.39.209222291079
  • Gale RE, Lamb K, Allen C, et al. Simpson‘s paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33(18):2072–2083. doi:10.1200/JCO.2014.59.202225964253
  • Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433. doi:10.1056/NEJMoa100514321067377
  • Tie R, Zhang T, Fu H, et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One. 2014;9(6):e93353. doi:10.1371/journal.pone.009335324936645
  • Kumar D, Mehta A, Panigrahi MK, Nath S, Saikia KK. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations. Hematol Oncol Stem Cell Ther. 2018;11(2):82–89. doi:10.1016/j.hemonc.2017.09.00429079128
  • Koya J, Kataoka K, Sato T, et al. DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nat Commun. 2016;7:10924. doi:10.1038/ncomms1092427010239
  • Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013;121(23):4769–4777. doi:10.1182/blood-2012-10-46162423632886
  • Ahn JS, Kim HJ, Kim YK, et al. DNMT3A R882 mutation with FLT3-ITD positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(1):61–70. doi:10.1016/j.bbmt.2015.07.03026234722
  • Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26(6):1247–1254. doi:10.1038/leu.2011.38222289988
  • Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889–2896. doi:10.1200/JCO.2011.35.489421670448

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.